Print the page



COMPACK (2014-2016)

NORGENOTECH University of Oslo LGCGEEurosafeimstar


Project: A new compact comet assay for versatile genotoxicity testing and environmental monitoring

The comet assay is the most widely used method for measuring DNA damage in eukaryotic cells. This test system is used for environmental agents as well as in human biomonitoring, for endogenous damage and antioxidant resistance analysis and DNA repair. The comet assay is employed by the pharmaceutical, cosmetic and chemical industries for screening novel drugs and chemicals for genotoxicity.

The ComPack project is a French-Norwegian collaborative research and innovation project that addresses the need for reliable and validated testing for industry and academia to assess the effect of chemicals on human health and the environment. The public-private consortium plans to develop by the end of 2016 a high throughput, automated, versatile, validated and user-friendly DNA testing facility based on the innovative modified comet assay.

Read the press release


COMPACK consortium

  • The project initiator, NorGenoTech AS (NGT) lead by Pr. Andrew Collins, Dr Gunnar Brunborg and Dr Sergey Shaposhnikov which facilities are based at the Department of Nutrition, Oslo University
  • The Department of Nutrition, part of the Medical Faculty of the University of Oslo
  • LGCgE – Equipe Sols et Environnement – Laboratoire Génie Civil et géo Environnement
  • Eurosafe, a CRO based in France, Britanny (that has recently acquired Xenoblis)
  • IMSTAR SA, a French private SME
 GENOTRACE (2014-2016)

 University Toulouse IIIBiopredicinraCNRS

Project: Real time in vitro evaluation of carcinogenic potential of contaminants.

Among the current short-term assays developed to assess DNA damage induced by a physical or chemical agent, the micronucleus assay (MN) represents a reliable and precise method that is already validated as a regulatory test in a battery of predictive tests for carcinogenesis. The Genotrace project aims at bringing major technological innovations to develop a new MN assay, that will allow to monitor both dynamically and in real time the production of chromosome damages and the signal of a genotoxic reporter on HepaRG™ cells. The developed in vitro MN assay will be adapted to a medium- to high throughput straightforward readable assay, thanks to the implementation of high content screening imaging protocols and the development of an image analysis and classification-based pipeline. The assay will bring new capacities to the classic MN assay and may lead to breakthroughs in the prevention and/or the diagnosis of exposure to genotoxicants present in the environment, food or future drug candidates.

Read the press release

Genotrace consortium

The public/ private Genotrace consortium includes
  •  Biopredic International
  •  the project initiator, INRA joint research unit « Food Toxicology » (Toxalim)
  •  the “Institut des technologies avancées en sciences du Vivant” (ITAV) of the CNRS 
  •  Toulouse III - Paul Sabatier university

 COMICS (2007-2010)



Project: The objective of this European funded project was the development of alternatives that replaced the need for animal experiments.

The methods developed have provided reliable in vitro assays for use in screening chemicals for potential genotoxic and cytotoxic effects,and have thus helped to limit the amount of animal experimentation that was to be carried out - notably, in connection with the EC policy on the Registration, Evaluation and Authorisation of Chemicals (REACH). The methods were subject to rigorous testing in order to meet international validation standards and to be accepted by industrial users and regulatory authorities.


Comics consortium


- University of Oslo


- Joint Research Unit

- Norwegian Institute of Public Health

- Institut national de la Santé et de la Recherche Médicale

- Slovak Medical University



- Astra Zeneca

- Thistle Scientific

- Severn Biotech

- Biopredic International

- Upsala University

- Institute of Experimental Batany


 BALANCE (2012-2015)


Project: Development of a Bioartificial liver therapy in acute liver failure.

The BALANCE project takes up the challenge of realising the clinical development of a BAL based on a human liver cell line that for the first time enables increased survival in patients with severe liver failure.BALANCE is a 3 year project organised in 3 stages.

Stage I: In vitro optimisation, validation and technical preparation of the HepaRG cell line in the bioreactor.

Stage II: Proof of safety and feasibility in an appropriate model of liver failure

Stage III: Proof of safety and feasibility in a phase I/IIa study in liver failure patients.



Balance consortium

- University of Amsterdam

- Hep-Art Medical Devices

- Pharmacell B.V.

- Royal Infirmary of Edinburgh

- Biopredic International


 NOTOX (2011-2016)


Project: Predicting long-term toxic effects using computer models based on systems characterization of organotypic cultures.

NOTOX is one of the building block projects of the European research initiative SEURAT (safety evaluation ultimately replacing animal testing) funded by EU-FP7 HEALTH programme and the European Cosmetics Association (Cosmetics Europe). The total funding for the cluster projects is 50 million €. This initiative with six projects as building blocks aims at the common strategy “towards the replacement of current repeated dose systemic toxicity testing in human safety assessment”.


Notox consortium

- Universität des Saarlandes

- Centre National de la Recherche Scientifique

- Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis

- Karolinska Institute

- Insilico Biotechnology AG

- Institut National de Recherche en   Informatique et en Automatique

- Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V

- Biopredic International


- Weizmann Institute of Science


- Cambridge Cell Networks Ltd


- European Research and Project Office GmbH


- Deutsches Forschungszentrum für Künstliche Intelligenz GmbH





Project: Development of in vitro test methods for identification of carcinogenic substances.

The aim of the FP6 project carcinoGENOMICS was to develop in vitro methods for assessing the carcinogenic potential of compounds, as an alternative to rodent bioassays for genotoxicity and carcinogenicity. The major goal was to develop a battery of mechanism-based in vitro tests accounting for various modes of carcinogenic action.
These tests have been designed to cover major target organs for carcinogenic action e.g. the liver, the lung and the kidney.


Carcinogenomics consortium


- Maastricht University

- University Hospital La FE, Valenciana

- Vrije Universteit Brussel

- Cellartis

- Leiden University Medical Centre

- University College Dublin

- Novozymes

- Imperial College, London



- TNO Quality of Life

- Max Planck Institute for molecular genetics

- Future Participant X

- European Comission - DG JRC - IHCP - ECVAM

- European Consensus Platform for Alternatives

- Unilever

- Innsbruck Medical University

- Genedata

- Biopredic International

- John Moores University


LIINTOP (2007- 2010)




Project: Optimisation of liver and intestine in vitro models for pharmacokinetics and pharmacodynamics studies.

The main aim of this project was to provide optimised established protocols and experimental in vitro models for testing intestinal and liver absorption, metabolism and toxicity of molecules of pharmacological interest. The added value of the project was to provide optimised sequential procedures, easily amenable to validation studies for screening and testing of new drugs, possibly be miniaturized and automated technology. The direct participation of SMEs in the research activities has assured that those procedures also fit with the requirements of industrial applications

Liintop consortium


- Consiglio nazionale delle ricerche

- Ente ospedaliero cantonale

- Fundacion para la investigacion del hospital universitario la fe de la comunidad Valenciana

- Biopredic International

- Inserm

- Helsingin Yliopisto

- University of Manchester

- Simcyp

- Istituto nazionale di ricerca per gli alimenti e la nutrizione

- Vrije universiteit Brussel

- Novamass analytical

- N.V. Organon

- Siena Biotech

- Advanced in vitro cell technologies

- Solvo Biotechnology


BIOPREDIC International   | | Phone: +33 (0)2 99 14 36 14 | Parc d'Affaires de la Bretèche 35760 Saint Grégoire FRANCE

Home  |  Search  |  Site Map  |  Legal disclaimer